Literature DB >> 9507837

Oral phentolamine as treatment for erectile dysfunction.

A J Becker1, C G Stief, S Machtens, D Schultheiss, U Hartmann, M C Truss, U Jonas.   

Abstract

PURPOSE: For most patients with erectile dysfunction oral agents are a preferred treatment option. Oral or buccal phentolamine has been shown to produce full erections in impotent subsets of study populations. We evaluate the efficacy of oral phentolamine.
MATERIALS AND METHODS: After a comprehensive evaluation 44 patients with recent onset (less than 3 years) of erectile dysfunction and a high likelihood of organogenic etiology underwent a prospective, double-blind and placebo controlled trial with oral phentolamine after placebo.
RESULTS: After placebo 4 of the 44 patients who reported full erections were excluded from study. Of the 40 patients in the double-blind phase full erections were achieved by 2 of 10 with placebo, and 3 of 10 with 20 mg., 5 of 10 with 40 mg. and 4 of 10 with 60 mg. phentolamine. There were no serious complications observed during the study, and only a single minor side effect occurred in 1 patient after 60 mg. phentolamine.
CONCLUSIONS: Our results indicate that oral phentolamine may be of benefit for the treatment of erectile dysfunction. Further studies are required to corroborate our findings.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507837

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Sildenafil and erectile dysfunction.

Authors:  A Fabbri; A Aversa; A Isidori
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

2.  Erectile dysfunction: diagnosis and management with newer oral agents.

Authors:  C C Carson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-10

Review 3.  Comparative tolerability and efficacy of treatments for impotence.

Authors:  W Meinhardt; R F Kropman; P Vermeij
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

4.  Apical dissection during radical retropubic prostatectomy without ligature.

Authors:  Christian G Stief
Journal:  World J Urol       Date:  2003-07-30       Impact factor: 4.226

5.  Enhancement of apomorphine-induced penile erection in the rat by a selective alpha(1D)-adrenoceptor antagonist.

Authors:  Hiroya Mizusawa; Petter Hedlund; Johan Sjunnesson; Jorge D Brioni; James P Sullivan; Karl-Erik Andersson
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 6.  Effects of alpha(1)-adrenoceptor antagonists on male sexual function.

Authors:  Marleen M van Dijk; Jean J M C H de la Rosette; Martin C Michel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.

Authors:  D Vitezic
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

8.  Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study.

Authors:  Sol Yoon; Jae Hwi Choi; Seung Hyun Lee; See Min Choi; Seong Uk Jeh; Sung Chul Kam; Jeong Seok Hwa; Ky Hyun Chung; Jae Seog Hyun
Journal:  World J Mens Health       Date:  2014-12-29       Impact factor: 5.400

9.  Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH).

Authors:  Angelo J Cambio; Christopher P Evans
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.